Studies in Parkinson have been suggested that dopaminergic neurons from substance nigra can be associated to GSH deficiency, becoming these cells more vulnerable to ROS [53]
Of the 20 papers included for the GLP-1 subsample, three studies included data from healthy participants, 10 included individuals with overweight and obesity, seven included individuals with T2D, four studies investigated GLP-1 in patients with gastric bypass, one included twins, and, one study included individuals with acquired hypothalamic damage
Its a small action with a truly significant impact
What's New: July 2026 Update TRIUMPH-4 confirmed as final: 28.7% weight loss at 68 weeks in 445 participants peer-reviewed Phase 3 data, December 2025 TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients reached 30.3% average weight loss weight loss does not plateau at 80 weeks TRANSCEND-T2D-1 CONFIRMED (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients, separate from the TRIUMPH obesity program OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour TRIUMPH-2 (obesity + diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results expected later in 2026 Introduction Retatrutide's clinical journey tells a story of escalating and now confirmed efficacy
The technology sector is represented but by less prominent stocks such as Broadcom (AVGO), IBM (IBM) and Qualcomm (QCOM)
Its deficiency is also one of the most common micronutrient abnormalities in PCOS worldwide, and its therapeutic significance is supported by a wealth of clinical and mechanistic data
